Ajanta Pharma

Who are the top shareholders of the Ajanta Pharma?

The top shareholders of Ajanta Pharma include Rajesh M Agrawal, who holds 14.47%, mutual funds with 15.13%, foreign institutional investors at 8.86%, and individual investors with 6.63%. The highest public shareholder is Uti-flexi Cap Fund, holding 2.96%.

The top shareholders of Ajanta Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Rajesh M Agrawal, Trustee of the Rajesh Agrawal Trust, with a stake of 14.47%. Additionally, mutual funds hold 15.13% of the shares through 28 schemes, while foreign institutional investors (FIIs) hold 8.86% across 313 entities. The highest public shareholder is Uti-flexi Cap Fund, which has a holding of 2.96%. Individual investors collectively hold 6.63% of the company's shares.

What does Ajanta Pharma do?

Ajanta Pharma Ltd. is a large-cap specialty pharmaceutical formulation company, reporting net sales of ₹1,170 Cr and a net profit of ₹225 Cr for Q1 2025. It has a market cap of ₹32,185 Cr and key metrics include a P/E ratio of 35.00 and a dividend yield of 1.09%.

Overview:<BR>Ajanta Pharma Ltd. is a specialty pharmaceutical formulation company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Large Cap entity.<BR><BR>History:<BR>Ajanta Pharma was incorporated in an unspecified year and has maintained its status as a specialty pharmaceutical company. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,170 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 225 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 32,185 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 35.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 1.09%<BR>- Debt-Equity: -0.13<BR>- Return on Equity: 25.39%<BR>- Price to Book: 8.89<BR><BR>Contact Details:<BR>- Address: Ajanta House, Charkop Kandivli (W) Mumbai Maharashtra : 400067<BR>- Phone: 91-22-66061000/1204/1203<BR>- Email: info@ajantapharma.com<BR>- Website: http://www.ajantapharma.com

What is the bonus history of the Ajanta Pharma?

Ajanta Pharma has issued bonuses twice, with the most recent being a 1:2 bonus announced on June 22, 2022, and a previous one also in a 1:2 ratio on September 17, 2013.

Ajanta Pharma has a history of issuing bonuses. The most recent bonus was a 1:2 bonus issue, which was announced with an ex-date of June 22, 2022, and a record date of June 23, 2022. Prior to that, the company also issued a bonus in a 1:2 ratio with an ex-date of September 17, 2013, and a record date of September 18, 2013. This indicates that Ajanta Pharma has engaged in bonus issues on two occasions in the past.

Has Ajanta Pharma declared dividend?

Yes, Ajanta Pharma has declared a dividend of 1400% (₹28 per share), with an ex-date of November 6, 2024. The company has shown positive total returns over various periods, particularly strong in the long term.

Ajanta Pharma has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1400%<BR>- Amount per share: 28<BR>- Ex-date: 06 Nov 24<BR><BR>Dividend Yield: 1.09%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -10.14%, with no dividend return, resulting in a total return of -10.14%.<BR><BR>Over the past year, the price return was 11.86%, with a dividend return of 1.17%, leading to a total return of 13.03%.<BR><BR>In the 2-year period, the price return was 82.4%, with a dividend return of 4.34%, culminating in a total return of 86.74%.<BR><BR>For the 3-year period, the price return was 125.36%, alongside a dividend return of 5.84%, resulting in a total return of 131.2%.<BR><BR>In the last 4 years, the price return was 99.3%, with a dividend return of 6.07%, giving a total return of 105.37%.<BR><BR>Over the past 5 years, the price return was 166.49%, with a dividend return of 9.55%, leading to a total return of 176.04%.<BR><BR>Overall, Ajanta Pharma's significant dividend declaration of 1400% indicates a strong commitment to returning value to shareholders, while the total returns over various periods reflect a generally positive performance, particularly in the longer term.

Who are the peers of the Ajanta Pharma?

Ajanta Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Piramal Pharma, Gland Pharma, J B Chemicals, and Pfizer. Key insights show excellent management risk and capital structure for several peers, with Divi's Lab leading in 1-year returns at 51.69%, while Ajanta Pharma has a 1-year return of 10.15%.

Peers: The peers of Ajanta Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Piramal Pharma, Gland Pharma, J B Chemicals &, Pfizer.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma, Dr Reddy's Labs, Sun Pharma.Inds., Cipla, Gland Pharma, and J B Chemicals &, while Average management risk is found at Piramal Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Ajanta Pharma, Torrent Pharma, Gland Pharma, and Pfizer show Below Average growth, and Divi's Lab. has Below Average growth as well. Capital Structure is Excellent for Ajanta Pharma, Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Gland Pharma, and J B Chemicals &, while it is Good for Torrent Pharma, Average for Piramal Pharma, and Below Average for Piramal Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Gland Pharma at -12.02%. Ajanta Pharma's 1-year return is 10.15%, which is lower than Divi's Lab. but higher than Gland Pharma. Additionally, Torrent Pharma, Piramal Pharma, Gland Pharma, and Cohance Life have negative six-month returns.

Is Ajanta Pharma overvalued or undervalued?

As of February 4, 2025, Ajanta Pharma is considered overvalued with a valuation grade of "expensive," reflected in its high PE ratio of 34.93, EV to EBITDA of 25.16, and Price to Book Value of 8.87, which exceed industry averages and are higher than peers like Cipla and Dr. Reddy's Labs.

As of 4 February 2025, Ajanta Pharma's valuation grade has moved from very expensive to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued based on its high valuation ratios. Key ratios include a PE Ratio of 34.93, an EV to EBITDA of 25.16, and a Price to Book Value of 8.87, all of which are significantly above industry averages.<BR><BR>In comparison to its peers, Ajanta Pharma's PE Ratio is slightly lower than Sun Pharma's 35.25 but much higher than Cipla's attractive PE of 22.99. Furthermore, its EV to EBITDA ratio is higher than that of both Cipla and Dr. Reddy's Labs, which stand at 15.93 and 12.87, respectively. Despite a recent positive stock performance relative to the Sensex over the past week, the overall valuation suggests that Ajanta Pharma remains overvalued in the current market landscape.

Who are in the management team of Ajanta Pharma?

As of March 2023, the management team of Ajanta Pharma includes Mannalal B Agrawal (Chairman), Madhusudan B Agrawal (Vice Chairman), Yogesh Agrawal (Managing Director), Rajesh M Agrawal (Joint Managing Director), and several independent directors. They oversee the company's operations and strategic direction.

As of March 2023, the management team of Ajanta Pharma includes the following individuals:<BR><BR>1. Mannalal B Agrawal - Chairman (Non-Executive)<BR>2. Madhusudan B Agrawal - Vice Chairman<BR>3. Yogesh Agrawal - Managing Director<BR>4. Rajesh M Agrawal - Joint Managing Director<BR>5. Gaurang Shah - Vice President & Company Secretary<BR>6. Chandrakanth M Khetan - Independent Director<BR>7. K H Viswanathan - Independent Director<BR>8. Prabhakar Dalal - Independent Director<BR>9. Anjana Grewal - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

How big is Ajanta Pharma?

As of 24th July, Ajanta Pharma Ltd. has a market capitalization of 33,980.00 Cr, with recent net sales of 4,648.10 Cr and a net profit of 920.39 Cr. The company reported shareholder's funds of 3,790.29 Cr and total assets of 4,828.52 Cr.

As of 24th July, Ajanta Pharma Ltd. has a market capitalization of 33,980.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Ajanta Pharma reported Net Sales of 4,648.10 Cr and a Net Profit of 920.39 Cr.<BR><BR>For the latest annual period, the company reported Shareholder's Funds of 3,790.29 Cr and Total Assets of 4,828.52 Cr.

How has been the historical performance of Ajanta Pharma?

Ajanta Pharma has shown consistent growth in net sales and profits, with net sales increasing from ₹2,055.37 Cr in March 2019 to ₹4,648.10 Cr in March 2025, and profit after tax rising from ₹386.97 Cr to ₹920.39 Cr during the same period. The company's earnings per share improved from ₹44.12 to ₹72.84, reflecting strong financial performance.

Answer:<BR>The historical performance of Ajanta Pharma shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Ajanta Pharma's net sales have increased from 2,055.37 Cr in March 2019 to 4,648.10 Cr in March 2025, indicating a strong upward trend. The total operating income followed a similar pattern, rising from 2,055.37 Cr in March 2019 to 4,648.10 Cr in March 2025. The company's operating profit (PBDIT) also saw significant growth, climbing from 587.51 Cr in March 2019 to 1,354.00 Cr in March 2025. Profit before tax increased from 514.27 Cr in March 2019 to 1,189.16 Cr in March 2025, while profit after tax rose from 386.97 Cr to 920.39 Cr during the same period. The earnings per share (EPS) improved from 44.12 in March 2019 to 72.84 in March 2025, reflecting enhanced profitability. On the balance sheet, total assets grew from 4,828.52 Cr in March 2025, up from 3,293.29 Cr in March 2020, while total liabilities increased from 1.49 Cr in March 2024 to 4,828.52 Cr in March 2025. The cash flow from operating activities also showed improvement, rising from 456.00 Cr in March 2020 to 1,157.00 Cr in March 2025, contributing to a net cash inflow of 47.00 Cr in March 2025. Overall, Ajanta Pharma has demonstrated robust growth in sales, profits, and cash flow over the years.

Is Ajanta Pharma technically bullish or bearish?

As of November 24, 2025, Ajanta Pharma's technical trend is mildly bearish, supported by mixed signals from MACD, RSI, and moving averages, despite some bullish indications on the monthly RSI.

As of 24 November 2025, the technical trend for Ajanta Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The RSI shows a bullish signal on the monthly timeframe, yet there is no signal on the weekly. Both the Bollinger Bands and KST are mildly bearish on both weekly and monthly timeframes. Moving averages on the daily are also mildly bearish, reinforcing the overall bearish sentiment. Dow Theory indicates no trend on the weekly and mildly bearish on the monthly. Overall, while there are some bullish signals on the monthly RSI, the prevailing indicators suggest a mildly bearish outlook.

When is the next results date for Ajanta Pharma Ltd.?

Ajanta Pharma Ltd. will announce its results on 05 May 2026.

Ajanta Pharma Ltd. is scheduled to declare its results on 05 May 2026.

Are Ajanta Pharma Ltd. latest results good or bad?

Ajanta Pharma Ltd.'s latest results show strong revenue growth with net sales increasing by 21.47% year-on-year, but profitability is a concern due to a decline in net profit and operating margins. Investors should watch for how the company manages these challenges moving forward.

Ajanta Pharma Ltd.'s latest results present a mixed picture. On one hand, the company achieved impressive net sales of ₹1,421.64 crores for the quarter, marking a 21.47% increase year-on-year and a 3.40% increase sequentially. This is the highest quarterly revenue in the company's recent history, indicating strong topline momentum.<BR><BR>However, there are significant concerns regarding profitability. The net profit for the quarter was ₹266.70 crores, which reflects an 18.40% increase year-on-year but a decline of 2.58% compared to the previous quarter. Additionally, the operating margin contracted to 23.45%, down from 27.80% in the prior quarter, raising questions about cost management and operational efficiency.<BR><BR>Overall, while the revenue growth is commendable, the margin compression and the sequential decline in profit suggest potential challenges ahead. Investors may need to monitor how the company addresses these margin pressures in future quarters.

Should I buy, sell or hold Ajanta Pharma Ltd.?

Which are the latest news on Ajanta Pharma?

Why is Ajanta Pharma Ltd. falling/rising?

As of 08-May, Ajanta Pharma Ltd. is facing a stock price decline to 3,032.20, down -1.56%, due to underperformance and reduced investor participation. Despite recent challenges, the stock has increased by +20.87% over the past year and remains above its moving averages, indicating a positive long-term trend.

As of 08-May, Ajanta Pharma Ltd. is experiencing a decline in its stock price, currently at 3,032.20, which reflects a change of -48.0 (-1.56%). This downward movement is attributed to several factors. The stock has underperformed its sector by -1.45% today and has been on a consecutive fall for the last two days, resulting in a total decline of -1.91% during this period. Additionally, there has been a noticeable decrease in investor participation, with delivery volume dropping by -26.18% compared to the 5-day average, indicating reduced trading activity and interest in the stock.<BR><BR>Despite these recent challenges, it is important to note that Ajanta Pharma has shown strong performance over longer periods. For instance, the stock has increased by +20.87% over the past year and has consistently outperformed the BSE500 index in the last three annual periods. Furthermore, it is trading above its moving averages, which suggests a generally positive trend over the longer term. However, the immediate factors contributing to the current decline include the recent underperformance, falling investor participation, and the stock's consecutive losses.